Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effectiveness, safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in subjects with locally advanced or metastatic solid tumors. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Histological or cytological diagnosis of a relevant tumor type as per the study protocol and not candidates for curative surgery or radiation therapy.
  • Available tumor tissue (archival or newly obtained core or excisional biopsy).
  • Adequate hematologic and end organ function as measured by laboratory screening panel in the 14 days prior to treatment.
  • Life expectancy greater than 12 weeks.
  • ECOG performance status of 0 to 1.
  • Adequate contraception for women of childbearing potential.
  • 6-month wash-out of prior anti-PD1/PDL-1 therapy.

Exclusion Criteria:

  • Concurrent active malignancy.
  • Major surgery within 4 weeks of treatment.
  • Subjects with active, known or suspected autoimmune diseases.
  • Prior treatment with CD137 agonists, anti-CTLA-4 and anti-TIGIT antibodies.
  • History of any Grade 3 or 4 immune-related AE toxicity from prior immunotherapy that resulted in treatment discontinuation.
  • History of immune-related adverse events that lead to discontinuation of anti-PD-1 or PDL-1 therapy.
  • Active infections of HIV, hepatitis B, hepatitis C.
  • Medical illness or abnormal laboratory finding that would, in the Study Investigator's judgement, increase the risk to the subject associated with participation in the study.
  • Pregnancy in female subjects.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Saravut Weroha, M.D., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Yujie Zhao, M.D., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Mahesh Seetharam, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20512718

Mayo Clinic Footer